Published: Wed, May 24, 2017
Money | By Armando Alvarado

EAM Investors LLC Takes Position in EXACT Sciences Co. (EXAS)

(PES) climbed 0.00% and its total traded volume was 0.79 million shares contrast to the average volume of 1.29 million shares. The correct version of this story can be read at

Other hedge funds have also recently made changes to their positions in the company. Panagora Asset holds 23,727 shares.

The counter witnessed a trading volume of 0.22 million shares versus an average volume of 0.32 million shares during last trading session. Exact Sciences Corporation (EXAS) now trades with a market capitalization of $3.60 Billion. Fil Limited stated it has 660,686 shares or 0.03% of all its holdings. Us Financial Bank De reported 252,978 shares. First Limited Partnership holds 0% or 94,081 shares in its portfolio. Geduld E E holds 15,000 shares or 0.11% of its portfolio.

Shares of EXACT Sciences Corporation (NASDAQ:EXAS) declined on May 18, 2017 to $29.45 per share.

Millrace Asset Gp Incorporated reported 64,939 shares.

Those who purchased shares of EXACT Sciences Corporation have certain options and should contact the Shareholders Foundation.

Exact Sciences Corporation (NASDAQ:EXAS)'s RSI (Relative Strength Index) is 60.28.

Bathroom Bill Passes as Amendment
Final House approval came on Monday, sending the modified bill to the Senate , which should easily support it. But the NFL, NBA, leading business lobbies and Hollywood celebrities have urged Texas to avoid the issue.

Since December 14, 2016, it had 1 buying transaction, and 10 sales for $1.56 million activity. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned "Buy" rating by Roth Capital on Friday, October 30.

The stock of EXACT Sciences Corporation (NASDAQ:EXAS) is a huge mover today!

In other news, SVP D Scott Coward sold 7,046 shares of the business's stock in a transaction on Monday, February 27th. The insider LIDGARD GRAHAM PETER sold $62,316. THOMPSON DAVID had bought 10,000 shares worth $138,400. Bancshares Of Montreal Can has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). We have $32.79 PT which if reached, will make NASDAQ:EXAS worth $170.50 million more. Analysts are forecasting earnings of $-0.37 on a per share basis this quarter. The share price has moved forward from its 20 days moving average, trading at a distance of 2.18% and stays 22.87% away from its 50 days moving average.

Exact Sciences Corporation is a molecular diagnostics company. Following the transaction, the insider now directly owns 314,527 shares of the company's stock, valued at approximately $6,765,475.77. Finally, United Services Automobile Association raised its stake in EXACT Sciences by 8.7% in the third quarter. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned "Buy" rating by Jefferies on Wednesday, July 27. Its last month's stock price volatility remained 3.61% which for the week approaches 3.58%. The Company focuses on the early detection and prevention of some forms of cancer. Equities research analysts anticipate that EXACT Sciences Co. will post ($1.35) earnings per share for the current fiscal year. Cologuard is a branded laboratory-based scan for DNA traces in stool samples, indicating colorectal cancer. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Therefore 50% are positive.

The company's consensus rating on Reuter's scale remained unchanged from 2.17 to 2.17 during a month. BTIG Research initiated EXACT Sciences Corporation (NASDAQ:EXAS) rating on Friday, December 18. United Services Automobile Association now owns 211,085 shares of the medical research company's stock worth $3,920,000 after buying an additional 16,900 shares during the period. The stock has "Neutral" rating by Mizuho on Wednesday, May 4. Goldman Sachs Group Inc set a $33.00 price objective on EXACT Sciences and gave the stock a "neutral" rating in a research report on Monday, May 1st. The rating was maintained by Canaccord Genuity with "Buy" on Monday, August 24. Benchmark upgraded the stock to "Buy" rating in Tuesday, February 21 report.

Among 14 analysts covering EXACT Sciences (NASDAQ:EXAS), 7 have Buy rating, 1 Sell and 6 Hold. They now have a Dollars 4 price target on the stock.

Like this: